455 related articles for article (PubMed ID: 31758423)
41. Prevalence of anti-peptidylarginine deiminase type 4 antibodies in rheumatoid arthritis and unaffected first-degree relatives in indigenous North American Populations.
Ferucci ED; Darrah E; Smolik I; Choromanski TL; Robinson DB; Newkirk MM; Fritzler MJ; Rosen A; El-Gabalawy HS
J Rheumatol; 2013 Sep; 40(9):1523-8. PubMed ID: 23908443
[TBL] [Abstract][Full Text] [Related]
42. Insights into the study and origin of the citrullinome in rheumatoid arthritis.
Fert-Bober J; Darrah E; Andrade F
Immunol Rev; 2020 Mar; 294(1):133-147. PubMed ID: 31876028
[TBL] [Abstract][Full Text] [Related]
43. The addition of iguratimod can reduce methotrexate dose in rheumatoid arthritis with clinical remission.
Yoshikawa A; Kotani T; Matsuda S; Hata K; Matsumura Y; Takeuchi T
Mod Rheumatol; 2022 Jan; 32(1):68-73. PubMed ID: 33627038
[TBL] [Abstract][Full Text] [Related]
44. Decreased severity of experimental autoimmune arthritis in peptidylarginine deiminase type 4 knockout mice.
Suzuki A; Kochi Y; Shoda H; Seri Y; Fujio K; Sawada T; Yamada R; Yamamoto K
BMC Musculoskelet Disord; 2016 May; 17():205. PubMed ID: 27150598
[TBL] [Abstract][Full Text] [Related]
45. IL-6-PAD4 axis in the earliest phase of arthritis in knock-in gp130F759 mice, a model for rheumatoid arthritis.
Yahagi A; Saika T; Hirano H; Takai-Imamura M; Tsuji F; Aono H; Iseki M; Morita Y; Igarashi H; Saeki Y; Ishihara K
RMD Open; 2019; 5(2):e000853. PubMed ID: 31321075
[TBL] [Abstract][Full Text] [Related]
46. Clinical and immunological aspects of anti-peptidylarginine deiminase type 4 (anti-PAD4) autoantibodies in rheumatoid arthritis.
Reyes-Castillo Z; Muñoz-Valle JF; Llamas-Covarrubias MA
Autoimmun Rev; 2018 Feb; 17(2):94-102. PubMed ID: 29196243
[TBL] [Abstract][Full Text] [Related]
47. Autocitrullination confers monocyte chemotactic properties to peptidylarginine deiminase 4.
Yoshida K; Ito H; Kurosaka D; Ikeda R; Noda K; Saito M; Kurosaka D
Sci Rep; 2023 May; 13(1):7528. PubMed ID: 37160933
[TBL] [Abstract][Full Text] [Related]
48. Citrullinated inter-alpha-trypsin inhibitor heavy chain 4 in arthritic joints and its potential effect in the neutrophil migration.
Osada A; Matsumoto I; Mikami N; Ohyama A; Kurata I; Kondo Y; Tsuboi H; Ishigami A; Sano Y; Arai T; Ise N; Sumida T
Clin Exp Immunol; 2021 Mar; 203(3):385-399. PubMed ID: 33238047
[TBL] [Abstract][Full Text] [Related]
49. Peptidyl arginine deiminase immunization induces anticitrullinated protein antibodies in mice with particular MHC types.
Arnoux F; Mariot C; Peen E; Lambert NC; Balandraud N; Roudier J; Auger I
Proc Natl Acad Sci U S A; 2017 Nov; 114(47):E10169-E10177. PubMed ID: 29109281
[TBL] [Abstract][Full Text] [Related]
50. The three-year efficacy of iguratimod in clinical daily practice in patients with rheumatoid arthritis.
Suto T; Yonemoto Y; Okamura K; Sakane H; Takeuchi K; Tamura Y; Kaneko T; Ayabe K; Chikuda H
Mod Rheumatol; 2019 Sep; 29(5):775-781. PubMed ID: 30092680
[No Abstract] [Full Text] [Related]
51. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages.
Vossenaar ER; Radstake TR; van der Heijden A; van Mansum MA; Dieteren C; de Rooij DJ; Barrera P; Zendman AJ; van Venrooij WJ
Ann Rheum Dis; 2004 Apr; 63(4):373-81. PubMed ID: 15020330
[TBL] [Abstract][Full Text] [Related]
52. Novel method to quantify peptidylarginine deiminase activity shows distinct citrullination patterns in rheumatoid and juvenile idiopathic arthritis.
Yu K; Dillemans L; Gouwy M; Bessa H; Metzemaekers M; Martens E; Matthys P; Bossuyt X; Verschueren P; Wouters C; De Somer L; Proost P
Front Immunol; 2023; 14():1111465. PubMed ID: 36793709
[TBL] [Abstract][Full Text] [Related]
53. Citrullinated proteins in rheumatoid arthritis.
Yamada R; Suzuki A; Chang X; Yamamoto K
Front Biosci; 2005 Jan; 10():54-64. PubMed ID: 15574347
[TBL] [Abstract][Full Text] [Related]
54. The monocyte cell surface is a unique site of autoantigen generation in rheumatoid arthritis.
Thomas MA; Naik P; Wang H; Giles JT; Girgis AA; Kim SY; Johnson TP; Curran AM; Crawford JD; Jahanbani S; Bingham CO; Robinson WH; Na CH; Darrah E
Proc Natl Acad Sci U S A; 2024 Apr; 121(17):e2304199121. PubMed ID: 38630712
[TBL] [Abstract][Full Text] [Related]
55. Expression of anti-Porphyromonas gingivalis peptidylarginine deiminase immunoglobulin G and peptidylarginine deiminase-4 in patients with rheumatoid arthritis and periodontitis.
Shimada A; Kobayashi T; Ito S; Okada M; Murasawa A; Nakazono K; Yoshie H
J Periodontal Res; 2016 Feb; 51(1):103-11. PubMed ID: 26094771
[TBL] [Abstract][Full Text] [Related]
56. The VICM biomarker is released from activated macrophages and inhibited by anti-GM-CSFRα-mAb treatment in rheumatoid arthritis patients.
Mortensen JH; Guo X; De Los Reyes M; Dziegiel MH; Karsdal MA; Bay-Jensen AC; White WI
Clin Exp Rheumatol; 2019; 37(1):73-80. PubMed ID: 30418117
[TBL] [Abstract][Full Text] [Related]
57. Peptidyl arginine deiminase expression and macrophage polarization following stimulation with citrullinated and malondialdehyde-acetaldehyde modified fibrinogen.
Aripova N; Duryee MJ; Hunter CD; Ryan EM; Daubach EC; Jones SQ; Bierman MM; Ragland AS; Mitra A; England BR; Romberger DJ; Thiele GM; Mikuls TR
Int Immunopharmacol; 2022 Sep; 110():109010. PubMed ID: 35785731
[TBL] [Abstract][Full Text] [Related]
58. Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis.
Chang X; Yamada R; Suzuki A; Sawada T; Yoshino S; Tokuhiro S; Yamamoto K
Rheumatology (Oxford); 2005 Jan; 44(1):40-50. PubMed ID: 15466895
[TBL] [Abstract][Full Text] [Related]
59. Characterization and use of the ECV304 autoantigenic citrullinome to understand anti-citrullinated protein/peptide autoantibodies in rheumatoid arthritis.
de França NR; Ménard HA; Lora M; Zhou Z; Rauch J; Hitchon C; Andrade LEC; Colmegna I
Arthritis Res Ther; 2022 Jan; 24(1):23. PubMed ID: 35027076
[TBL] [Abstract][Full Text] [Related]
60. Reduced glutathione as a physiological co-activator in the activation of peptidylarginine deiminase.
Damgaard D; Bjørn ME; Steffensen MA; Pruijn GJ; Nielsen CH
Arthritis Res Ther; 2016 May; 18(1):102. PubMed ID: 27149996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
